Latest stories on ALLO
Allogene rises as FDA offers Fast Track, RMAT tags to cell therapy
Seeking Alpha67 · bullishproduct/pr
Allogene Therapeutics stock rises on FDA regulatory designations
Investing.com Markets67 · bullishgeneral
ALLOSOURCE® INTRODUCES FDA 510(K) CLEARED RECONNEX™ PRE-SUTURED TENDON FOR ALL-INSIDE ANTERIOR CRUCIATE LIGAMENT PROCEDURES
PR Newswire56 · neutralproduct/pr
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Seeking Alpha67 · bullishanalyst
Recent pharma exec shake-ups signal strategic shifts
Yahoo Finance42 · neutralgeneral
Allogene Launches ATM Offering to Bolster Capital Flexibility
TipRanks28 · bearishgeneral
Allogene Therapeutics, Inc. (ALLO) files 8-K
SEC 8-K50 · neutralgeneral
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease
Yahoo Top63 · neutralproduct/pr
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio
Yahoo Top58 · neutralanalyst
Allogene Therapeutics Names Zachary Roberts as New CEO
TipRanks55 · neutralgeneral
Allogene Therapeutics names Zachary Roberts CEO in planned succession
Seeking Alpha50 · neutralgeneral
Allogene Therapeutics Announces Planned CEO Succession | ALLO Stock News
StockTitan55 · neutralgeneral
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences | ALLO Stock News
StockTitan55 · neutralgeneral
Allogene Earnings Call Highlights Early CAR-T Momentum
TipRanks56 · neutralearnings
Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M
Seeking Alpha56 · neutralgeneral
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Allogene Therapeutics Q1 Earnings Call Highlights
Yahoo Finance56 · neutralearnings
Allogene Therapeutics GAAP EPS of -$0.18 beats by $0.01
Seeking Alpha56 · neutralearnings